膀胱がん治療および診断市場- 世界の産業規模、シェア、動向、機会、予測、治療別、診断別、がんタイプ別、地域別セグメント、競合、2020年～2030年

世界の膀胱がん治療および診断市場は、2024年に4億5,022万米ドルと評価され、2030年までのCAGRは7.50%で、予測期間中に目覚ましい成長を示すと予測されています。

膀胱の内壁にある健康な細胞（多くは尿路上皮細胞）が制御不能に変化・拡大し、腫瘍として知られる腫瘤を形成すると、膀胱がんが発症します。腎盂、尿管、尿道はすべて尿路上皮細胞で覆われています。尿路上皮がんのもう一つの形態は、上部尿路上皮がんと呼ばれ、腎盂と尿管に発生するがんです。このがんは、このガイダンスで膀胱がんについて述べたような方法で治療されることが多いです。腫瘍には良性と悪性があります。悪性とは、がん腫瘍が発生し、体のさまざまな部位に転移する能力を指します。腫瘍が良性の場合は、大きくなることはあっても転移することはありません。良性の膀胱腫瘍が発生することはまれです。膀胱がんの世界の罹患率の上昇、特に高齢化が大きな原動力となっています。膀胱がんの症例数の増加は、より多くの患者を生み出し、診断薬と治療薬の需要を促進しています。

画像診断技術の向上、尿ベースのバイオマーカー検査、遺伝子プロファイリングなどの診断技術の継続的な改善により、膀胱がんの早期発見・診断が向上し、診断薬に対する需要が増加しています。免疫療法（チェックポイント阻害薬など）や標的治療などの新規治療アプローチの開発により、治療の選択肢が拡大し、膀胱がん患者の転帰が改善されています。こうした技術革新が市場成長の原動力となっています。新たな治療法、併用療法、個別化医療アプローチを模索するための進行中の臨床試験や研究イニシアティブは、市場拡大の機会を生み出しています。世界人口の高齢化は膀胱がんに罹患しやすくなります。高齢者人口の増加に伴い、膀胱がんの有病率は増加すると予想され、治療および診断に対する需要の高まりにつながっています。

主な市場促進要因

革新的治療法の増加

主な市場課題

高い治療費

主な市場動向

低侵襲手術技術

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の膀胱がん治療および診断市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 治療別（化学療法、免疫療法、その他の治療薬）
  • 診断別（膀胱鏡検査、膀胱超音波検査、尿検査、その他の診断法）
  • がんタイプ別（移行上皮がん、扁平上皮がん、その他のがんの種類）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 アジア太平洋地域の膀胱がん治療および診断市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州の膀胱がん治療および診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米の膀胱がん治療および診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米の膀胱がん治療および診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの膀胱がん治療および診断市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の膀胱がん治療および診断市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 PESTEL分析

第16章 競合情勢

• Ameritech Diagnostic Reagent（Jiaxing）Co., Ltd
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline PLC
• Novartis International AG
• Pfizer Inc.
• Abbott Inc.
• Endo Pharmaceuticals Inc.
• Johnson & Johnson（Janssen Pharmaceutical）
• Merck & Co. Inc
• Astellas Pharma Inc.

第17章 戦略的提言

第18章 調査会社について・免責事項

Global Bladder Cancer Therapeutics and Diagnostics Market was valued at USD 450.22 million in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 7.50% through 2030. When healthy cells in the bladder lining most frequently urothelial cells change and expand uncontrollably, forming a mass known as a tumor, bladder cancer develops. The renal pelvis, ureters, and urethra are all lined with urothelial cells. Another form of urothelial cancer, known as upper tract urothelial carcinoma, is cancer that originates in the renal pelvis and ureters. It is often treated in a manner like that discussed in this guidance for bladder cancer. A tumor may be benign or malignant. Malignant refers to the ability of a cancerous tumor to develop and metastasize to different body regions. If a tumor is benign, it can enlarge but won't spread. Rarely do benign bladder tumors occur. A rising global incidence of bladder cancer, especially in aging populations, has been a significant driver. The growing number of bladder cancer cases creates a larger patient pool, driving demand for diagnostics and therapeutics.

Continuous improvements in diagnostic techniques, including enhanced imaging technologies, urine-based biomarker tests, and genetic profiling, have improved early detection and diagnosis of bladder cancer, thereby increasing the demand for diagnostics. The development of novel therapeutic approaches, such as immunotherapies (e.g., checkpoint inhibitors) and targeted therapies, has expanded treatment options and improved outcomes for bladder cancer patients. These innovations drive market growth. Ongoing clinical trials and research initiatives to explore new treatments, combination therapies, and personalized medicine approaches create opportunities for market expansion. The aging global population is more susceptible to bladder cancer. As the elderly population grows, the prevalence of bladder cancer is expected to increase, leading to higher demand for therapeutics and diagnostics.

Key Market Drivers

Increasing Innovative Therapies

Innovative therapies in cancer therapeutics and diagnostics have transformed the way cancer is diagnosed and treated. These groundbreaking approaches offer new hope for patients and have the potential to improve outcomes while reducing side effects. For instance, according to Cancer Research UK, approximately 90% of bladder cancers in the UK are urothelial cancers, also called transitional cell cancers. Immunotherapy harnesses the body's immune system to target and destroy cancer cells. Immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell therapy, and cancer vaccines are among the most promising approaches. These therapies have shown remarkable results in various cancers, including melanoma, lung cancer, and leukemia. Precision medicine, also known as personalized medicine, tailors cancer treatment based on a patient's genetic, genomic, and molecular profile. Targeted therapies, such as tyrosine kinase inhibitors and PARP inhibitors, are designed to specifically target the genetic mutations or abnormalities driving a patient's cancer. Gene therapy involves the introduction or modification of genes to treat or prevent diseases, including cancer. CAR-T cell therapy is a prime example, where a patient's T cells are genetically engineered to target cancer cells with precision. Cancer vaccines stimulate the immune system to recognize and attack cancer cells. Therapeutic cancer vaccines aim to treat existing cancer, while preventive vaccines, like the HPV vaccine, prevent certain cancers from developing. Liquid biopsies involve analyzing blood, urine, or other bodily fluids to detect cancer-specific biomarkers, including circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs). These tests are minimally invasive and can provide insights into a patient's cancer status, treatment response, and minimal residual disease. Innovations in radiation therapy, such as intensity-modulated radiation therapy (IMRT), stereotactic body radiation therapy (SBRT), and proton therapy, allow for highly targeted radiation delivery, minimizing damage to healthy tissue.

Key Market Challenges

High Treatment Costs

The financial burden associated with bladder cancer diagnosis and treatment affects not only patients but also healthcare systems and society. The diagnostic process for bladder cancer often includes multiple procedures, such as cystoscopy, imaging (CT scans, MRI), urine tests, and potentially invasive biopsies. These diagnostic tests and procedures can accumulate substantial costs. Bladder cancer treatment options vary depending on the stage and type of cancer. Treatments may include surgery, chemotherapy, radiation therapy, immunotherapy, or a combination of these approaches. Each of these treatment modalities carries its own cost implications. Surgical procedures for bladder cancer, whether open or minimally invasive, can be expensive. Costs include surgeon fees, operating room expenses, anesthesia, and hospitalization. Immunotherapy and targeted therapies, while offering promising outcomes, can be expensive due to the high cost of drug development and administration. Some of these treatments are administered over an extended period. External beam radiation therapy and brachytherapy are common treatments for bladder cancer. The cost of radiation therapy includes the use of specialized equipment and personnel. The cost of chemotherapy drugs, as well as the monitoring and management of side effects, can be a significant financial burden on patients and healthcare systems. Bladder cancer patients often require long-term surveillance and monitoring for recurrence. This includes regular check-ups, imaging, and urine tests, which can add to the overall cost of care.

Key Market Trends

Minimally Invasive Surgical Techniques

Minimally invasive surgical techniques, such as laparoscopic and robotic-assisted surgery, often result in smaller incisions, less pain, and faster recovery times compared to open surgery. This leads to improved post-operative outcomes and a better quality of life for bladder cancer patients. Minimally invasive procedures typically require shorter hospital stays, reducing healthcare costs and freeing up hospital resources for other patients. Robotic-assisted surgery allows for precise removal of bladder tumors while preserving healthy tissue. This is especially important for patients with non-muscle-invasive bladder cancer (NMIBC) where tumor recurrence is a concern. Smaller incisions and reduced tissue trauma lower the risk of surgical site infections, which is a significant concern in open surgeries. Patients who undergo minimally invasive procedures often experience quicker recoveries, enabling them to return to their daily activities and work sooner. Minimally invasive techniques are associated with less pain and discomfort during the post-operative period, reducing the need for heavy pain medications. Smaller incisions result in less visible scarring, which can be particularly important for patients' body image and self-esteem. Laparoscopic and robotic systems provide surgeons with enhanced visualization of the surgical site, allowing for more precise tumor removal and reduced damage to healthy tissue.

Key Market Players

• Ameritech Diagnostic Reagent (Jiaxing)Co., Ltd
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd
• GlaxoSmithKline PLC
• Novartis International AG
• Pfizer Inc.
• Abbott Inc.
• Endo Pharmaceuticals Inc.
• Johnson & Johnson (Janssen Pharmaceutical)
• Merck & Co. Inc
• Astellas Pharma Inc.

Report Scope:

In this report, the Global Bladder Cancer Therapeutics and Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bladder Cancer Therapeutics and Diagnostics Market, By Therapeutics:

• Chemotherapy
• Immunotherapy
• Other Therapeutics

Bladder Cancer Therapeutics and Diagnostics Market, By Diagnostics:

• Cystoscopy
• Bladder Ultrasound
• Urinalysis
• Other Diagnostics

Bladder Cancer Therapeutics and Diagnostics Market, By Cancer Type:

• Transitional Cell Bladder Cancer
• Squamous Cell Bladder Cancer
• Other Cancer Types

Bladder Cancer Therapeutics and Diagnostics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bladder Cancer Therapeutics and Diagnostics Market.

Available Customizations:

Global Bladder Cancer Therapeutics and Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bladder Cancer Therapeutics and Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Therapeutics (Chemotherapy, Immunotherapy, Other Therapeutics)
  • 5.2.2. By Diagnostics (Cystoscopy, Bladder Ultrasound, Urinalysis, Other Diagnostics)
  • 5.2.3. By Cancer Type (Transitional Cell Bladder Cancer, Squamous Cell Bladder Cancer, Other Cancer Types)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Bladder Cancer Therapeutics and Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Therapeutics
  • 6.2.2. By Diagnostics
  • 6.2.3. By Cancer Type
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Therapeutics
      • 6.3.1.2.2. By Diagnostics
      • 6.3.1.2.3. By Cancer Type
  • 6.3.2. India Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Therapeutics
      • 6.3.2.2.2. By Diagnostics
      • 6.3.2.2.3. By Cancer Type
  • 6.3.3. Australia Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Therapeutics
      • 6.3.3.2.2. By Diagnostics
      • 6.3.3.2.3. By Cancer Type
  • 6.3.4. Japan Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Therapeutics
      • 6.3.4.2.2. By Diagnostics
      • 6.3.4.2.3. By Cancer Type
  • 6.3.5. South Korea Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Therapeutics
      • 6.3.5.2.2. By Diagnostics
      • 6.3.5.2.3. By Cancer Type

7. Europe Bladder Cancer Therapeutics and Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Therapeutics
  • 7.2.2. By Diagnostics
  • 7.2.3. By Cancer Type
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Therapeutics
      • 7.3.1.2.2. By Diagnostics
      • 7.3.1.2.3. By Cancer Type
  • 7.3.2. Germany Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Therapeutics
      • 7.3.2.2.2. By Diagnostics
      • 7.3.2.2.3. By Cancer Type
  • 7.3.3. Spain Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Therapeutics
      • 7.3.3.2.2. By Diagnostics
      • 7.3.3.2.3. By Cancer Type
  • 7.3.4. Italy Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Therapeutics
      • 7.3.4.2.2. By Diagnostics
      • 7.3.4.2.3. By Cancer Type
  • 7.3.5. United Kingdom Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Therapeutics
      • 7.3.5.2.2. By Diagnostics
      • 7.3.5.2.3. By Cancer Type

8. North America Bladder Cancer Therapeutics and Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Therapeutics
  • 8.2.2. By Diagnostics
  • 8.2.3. By Cancer Type
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Therapeutics
      • 8.3.1.2.2. By Diagnostics
      • 8.3.1.2.3. By Cancer Type
  • 8.3.2. Mexico Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Therapeutics
      • 8.3.2.2.2. By Diagnostics
      • 8.3.2.2.3. By Cancer Type
  • 8.3.3. Canada Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Therapeutics
      • 8.3.3.2.2. By Diagnostics
      • 8.3.3.2.3. By Cancer Type

9. South America Bladder Cancer Therapeutics and Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Therapeutics
  • 9.2.2. By Diagnostics
  • 9.2.3. By Cancer Type
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Therapeutics
      • 9.3.1.2.2. By Diagnostics
      • 9.3.1.2.3. By Cancer Type
  • 9.3.2. Argentina Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Therapeutics
      • 9.3.2.2.2. By Diagnostics
      • 9.3.2.2.3. By Cancer Type
  • 9.3.3. Colombia Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Application

10. Middle East and Africa Bladder Cancer Therapeutics and Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Therapeutics
  • 10.2.2. By Diagnostics
  • 10.2.3. By Cancer Type
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Therapeutics
      • 10.3.1.2.2. By Diagnostics
      • 10.3.1.2.3. By Cancer Type
  • 10.3.2. Saudi Arabia Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Therapeutics
      • 10.3.2.2.2. By Diagnostics
      • 10.3.2.2.3. By Cancer Type
  • 10.3.3. UAE Bladder Cancer Therapeutics and Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Therapeutics
      • 10.3.3.2.2. By Diagnostics
      • 10.3.3.2.3. By Cancer Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Bladder Cancer Therapeutics and Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Ameritech Diagnostic Reagent (Jiaxing)Co., Ltd
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Bristol-Myers Squibb Company
• 16.3. Eli Lilly and Company
• 16.4. F. Hoffmann-La Roche Ltd
• 16.5. GlaxoSmithKline PLC
• 16.6. Novartis International AG
• 16.7. Pfizer Inc.
• 16.8. Abbott Inc.
• 16.9. Endo Pharmaceuticals Inc.
• 16.10.Johnson & Johnson (Janssen Pharmaceutical)
• 16.11. Merck & Co. Inc
• 16.12. Astellas Pharma Inc.

17. Strategic Recommendations

18. About Us & Disclaimer